Bictegravir
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H18F3N3O5 |
| Molar mass | 449.386 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Bictegravir (INN; formerly known as GS-9883)[1][2] is an investigational new drug of the integrase inhibitor class that was discovered by scientists at Gilead Sciences; in vitro and clinical results were presented by Gilead in the summer of 2016.[3] In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection[4] and the combination drug bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) was approved for use in the United States in 2018.[5]
References
- ^ "Recommended INN: List 75" (PDF). WHO Drug Information. 30 (1): 102. 2016.
- ^ "Bictegravir". AdisInsight. Retrieved 22 January 2017.
- ^ Highleyman, Liz (6 July 2016). "New integrase inhibitor bictegravir looks promising in early studies". NAM aidsmap.
- ^ "Press Release: Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV | Gilead". Gilead. June 20, 2016.
- ^ "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection" (Press release). Gilead. February 7, 2018.
Further reading
- Tsiang, M; et al. (December 2016). "Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile". Antimicrobial Agents and Chemotherapy. 60 (12): 7086–7097. PMC 5118987. PMID 27645238.
{{cite journal}}: Explicit use of et al. in:|first1=(help)
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |